Publication: Methotrexate Versus Methotrexate Plus Folic Acid in the Treatment of Moderate to Severe Plaque Psoriasis: A Randomized Clinical-Trial
| creativeworkseries.issn | ISSN 2091-0231 eISSN 2091-167X | |
| dc.contributor.author | Khadka, D.K. | |
| dc.contributor.author | Agrawal, S. | |
| dc.contributor.author | Dhali, T.K. | |
| dc.date.accessioned | 2025-08-21T06:21:01Z | |
| dc.date.available | 2025-08-21T06:21:01Z | |
| dc.date.issued | 2016 | |
| dc.description | D.K. Khadka Assistant Professor, Department of Dermatology and Venereology, B. P. Koirala Institute of Health Sciences, Dharan S. Agrawal Professor and Head, Department of Dermatology and Venereology, B. P. Koirala Institute of Health Sciences, Dharan T.K. Dhali Associate Professor, Department of Dermatology and Venereology, ESIC PGIMSR, New Delhi | |
| dc.description.abstract | Abstract: Background: Psoriasis is a chronic, recurring inflammatory disease affecting the skin, joints and nails that has a significant negative impact on the quality of life. Efficacy of methotrexate versus combination of methotrexate plus folic acid in the treatment of psoriasis has been rarely assessed. Objectives: To compare the efficacy of methotrexate versus methotrexate plus folic acid in the treatment of moderate to severe chronic plaque psoriasis Material and Methods: Eighty patients with moderate to severe chronic plaque psoriasis were randomized to receive either methotrexate (group A) or methotrexate plus folic acid (group B). End point of treatment was 75% reduction in Psoriasis Area and Severity Index (PASI 75) score or upto 3 months, whichever was earlier. Patients were then followed up for a period of 12 weeks for assessment of relapse, DLQI and adverse effects. Results: Of 80 patients, 71 completed the treatment and follow up period (33 in group A, and 38 in group B). PASI 75 was achieved in 34/40(85%) patients in group A and 32/40(80%) patients in group B (P < 0.142). There was statistically significant number of patients who had greater adverse effect in methotrexate than in methotrexate plus folic acid (p=0.020). There was significant difference in the number of patients who relapsed during the follow-up period (P = 0.013) with more relapse in group B. Conclusion: Combination of methotrexate and folic acid developed lesser adverse effect and greater relapse in comparison to methotrexate alone. Keywords: DLQI, Folic acid, Methotrexate, PASI, Psoriasis | |
| dc.identifier | https://doi.org/10.3126/njdvl.v14i1.15835 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14572/1859 | |
| dc.language.iso | en_US | |
| dc.publisher | Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON) | |
| dc.title | Methotrexate Versus Methotrexate Plus Folic Acid in the Treatment of Moderate to Severe Plaque Psoriasis: A Randomized Clinical-Trial | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.article.type | Original Article | |
| oaire.citation.endPage | 36 | |
| oaire.citation.startPage | 29 | |
| relation.isJournalIssueOfPublication | 7a870830-8c7d-4b7d-a898-6c66091bdf86 | |
| relation.isJournalIssueOfPublication.latestForDiscovery | 7a870830-8c7d-4b7d-a898-6c66091bdf86 | |
| relation.isJournalOfPublication | b2ab7aab-75b0-4bd1-9ed0-b8a91c68201a |